system: You are a contract-analysis assistant performing a span-extraction task. You are given an excerpt from a commercial contract and the name of a clause type to locate within it.

Return the exact text of the requested clause, copied verbatim from the excerpt — identical wording and punctuation, with no paraphrasing, summarising, explanation, or added commentary.

The excerpt is one window of a much longer contract and often will not contain the requested clause. If the requested clause does not appear in this excerpt, respond with exactly: Not found.

Output only the extracted clause text, or the exact string `Not found.` — nothing else.

user: Contract excerpt:
"""
in Section 2.4.1. 1.1.9 "Approved Third Party Vendor Costs" has the meaning ascribed to such term in Section 5.2.2.2(g). 1.1.10 "Approved Vendor" has the meaning ascribed to such term in Section 2.4.2. 1.1.11 "AstraZeneca Product" has the meaning ascribed to such term in the AZ License. 1.1.12 "AstraZeneca Product Improvements" has the meaning ascribed to such term in the AZ License. 1.1.13 "AstraZeneca Product Know-How" has the meaning ascribed to such term in the AZ License. 1.1.14 "AstraZeneca Product Patents" has the meaning ascribed to such term in the AZ License. Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020 1.1.15 "AstraZeneca Product References" has the meaning ascribed to such term in the AZ License. 1.1.16 "AZ License" means the License Agreement between MedImmune and PB dated November 21, 2017, a copy of which is attached hereto as Exhibit L, as amended by that certain First Amendment to License Agreement dated January 9, 2020, a copy of which is attached hereto as Exhibit M. 1.1.17 "BLA" means: (a) a biologics license application submitted to the FDA pursuant to Section 351(a) of the PHSA and the regulations promulgated thereunder, or its successor application; or (b) an application for authorization to market and/or sell a biological product in any country or regulatory jurisdiction other than the US submitted to the applicable Regulatory Authority in such country or regulatory jurisdiction, including, with respect to the EU, a marketing authorization application submitted either (i) to the EMA pursuant to the centralized EU filing procedure or (ii) to the applicable national Regulatory Authority in an individual EU member state if the centralized EU filing procedure is not used. 1.1.18 "Brilinta Competing Product" means any P2Y12 receptor antagonist, other than the AstraZeneca Product or Generic Ticagrelor Product. 1.1.19 "Business Day" means a day that is not a Saturday, Sunday or a US federal holiday. 1.1.20 "Buy-Out Payment" means an Approval Buy-Out Payment or a Change of Control Buy-Out Payment. 1.1.21 "Calendar Quarter" means each successive period of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31; provided, that, the (a) the first Calendar Quarter shall begin on the Effective Date and end on the last day of the Calendar Quarter in which the Effective Date falls, and (b) the final Calendar Quarter shall end on the last day of the Term. 1.1.22 "Calendar Year" means each successive period of twelve (12) months commencing on January 1 and ending on December 31; provided, that, (a) the first Calendar Year shall begin on the Effective Date and end on December 31 of the Calendar Year in which the Effective Date falls, and (b) the final Calendar Year shall end on the last day of the Term. 1.1.23 "Case Report Form" or "CRF" means the collection of documents designed specifically for recording data pursuant to the Protocol. A CRF is completed for each Subject and will be in electronic form, validated and in compliance with all Applicable Laws. 1.1.24 "CFC" means a "controlled foreign corporation" as defined in the IRC. 1.1.25 "Change of Control" means, with respect to PB, at any time prior to the date of the payment by PB of the final Approval Payment hereunder, (a) a merger, reorganization or consolidation with a Third Party which results in the voting securities of PB outstanding Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020 immediately prior thereto ceasing to represent, or being converted into or exchanged for voting securities that do not represent, at least fifty percent (50%) of the combined voting power of the voting securities of the surviving entity or the parent corporation of the surviving entity immediately after such merger, reorganization or consolidation, (b) a transaction in which a Third Party becomes the beneficial owner of fifty percent (50%) or more of the combined voting power of the outstanding securities of PB, other than through the issuance of voting securities for the purpose of raising financing to one or more financial or institutional investors that are not then controlled by an entity engaged in the development or commercialization of pharmaceutical or biotechnology products, or (c) the sale or other transfer of all or substantially all of PB's business or assets relating to the Product for use in the Indication. A Licensing Transaction shall not constitute a Change of Control, unless such Licensing Transaction includes the grant of US Commercialization Rights in which event such Licensing Transaction shall be deemed to be a Change in Control. 1.1.26 "Change of Control Buy-Out Payment" has the meaning
"""

Extract the exact clause related to "Price Restrictions" from the excerpt above.

assistant: Not found.